| Completed | 1 | 66 | Europe | Natalizumab, Tysabri, Placebo: normal saline | King's College London, South London and Maudsley NHS Foundation Trust | Schizophrenia | 06/23 | 08/23 | | |
NCT05618301: Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD) |
|
|
| Recruiting | 1 | 10 | US | Motixafortide, BL-8040, Natalizumab, Tysabri, Leukapheresis | Washington University School of Medicine, BioLineRx, Ltd., Biogen | Sickle Cell Disease | 12/25 | 12/25 | | |
